PPIG and cancer: The PBPK DDI simulations were conducted between repeated doses (400 mg QD) of fedratinib and single doses of probe substrates for CYP enzymes in healthy subjects (using the Simcyp “Healthy Volunteers” population file) and cancer patients (using the Simcyp “Cancer” population file) following the simulation design listed in Supplemental Material SM5.